Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
2005-001340-22Phase 2Unknown
- Sponsor
- Bayhill Therapeutics, Inc.
- Start
- Jul 2005
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bht-3009 in multiple sclerosis (MS), sponsored by Bayhill Therapeutics, Inc. Primary endpoints: Mean four-week rate of occurrence of new gadolinium-enhancing lesions (Weeks 28–48) and Safety and tolerability of BHT-3009 over one year. Status: unknown.
02
Drugs
bht-3009
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-001340-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001340-22.